Catalyst Biosciences receives a notice of allowance from the Japan patent office (JPPO) covering modified factor X polypeptides
Wednesday, October 24, 2018 Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications,
Read More